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Abstract: Fucoidan, a fucose-rich polysaccharide from brown algae, has been used for transdermal 
formulations targeting inflammatory skin conditions, for the treatment of thrombosis, vascular 
permeability diseases, subcutaneous wounds, and burns. However, the pharmacokinetics of 
fucoidan after topical application has not been described. In this study, an ointment (OF) 
containing 15% fucoidan was topically applied to rats at the doses of 50–150 mg/g. The anti-Xa 
activity was selected as the biomarker, and the amidolytic assay method was validated and applied 
for pharmacokinetic studies of fucoidan. Fucoidan in OF penetrated the skin and distributed into 
the skin, striated muscle, and plasma with AUC0–48 = 0.94 μg·h/g, 2.22 μg·h/g, and 1.92 μg·h/mL, 
respectively. The longest half-life for fucoidan was observed in plasma, then in striated muscle and 
skin. It was found that the pharmacokinetics of fucoidan after topical OF application was linear, in 
the range of 50–150 mg/kg. No accumulation of fucoidan in plasma was observed after repeated 
topical applications of 100 mg/kg during five days. Our results support the rationality of topical 
application of formulations with fucoidan. 
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1. Introduction 
Fucoidans are one of the main fucose-rich polysaccharides isolated from Ascophyllum spp., 
Fucus spp., Laminaria spp., Undaria spp., and other brown algae. An attractive array of biological 
activities of fucoidan has been reported for its immune modulation, inhibition of tumor cells, blood 
lipid-reduction, treatment of age-related macular degeneration, antioxidant activity, antimicrobial 
properties, anti-viral vaccine adjuvant, etc. [1–6].  
Topical application of fucoidan exerts an anti-inflammatory effect on the skin. Fucoidan 
inhibits the expression of ultraviolet (UV) matrix metalloprotease in human skin fibroblasts [7] and 
human keratinocytes [8]. Fucoidan has showed similar inhibition of human dermal fibroblast 
proliferation in vitro as heparin [9]. Fucoidan-rich F. vesiculosus and U. pinnatifida extracts were 
shown to be effective inhibitors of elastase (IC50 < 100 μg/mL), tyrosinase (IC50 < 50 μg/mL), and 
collagenase [10]. Fucoidan from U. pinnatifida (0.3% in acetone/olive oil mixture) showed potent 
activity for the treatment of atopic dermatitis in the NC/Nga mice model [11]. The fucospheres 
containing 2% of fucoidan and 0.75% of chitosan have been used for the treatment of dermal heat 
burns in rabbits. The application of fucospheres lead to fast skin regeneration due to the effect of 
fucoidan on the migration of fibroblasts, release of growth hormones and cytokines involved in the 
re-epithelialization [12]. Ex vivo experiments with human skin confirmed that fucoidan limits 
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human dermal elastic network degradation by human leukocyte elastase, and protects dermal 
elastic fibers against human leukocyte elastase hydrolysis [13]. 
Fitton et al. have shown in double-blind, placebo-controlled clinical studies that gel with 0.3% 
fucoidans from U. pinnatifida or F. vesiculosus is highly effective in inhibiting the erythema and 
water loss caused by UV-induced inflammation [10]. In patients with atopic dermatitis, it was 
shown that fucoidan mediates suppression of IgE in blood cells [14]. The cream containing 4% 
fucoidan from Nemacystus decipiens was found to be effective after topical application in the 
treatment of patients with oral herpes [15]. 
Thus, fucoidan has been used in transdermal formulations targeting inflammatory skin 
conditions, for treatment of superficial thrombosis, vascular permeability diseases, subcutaneous 
wounds, and burns [1]. The use of anticoagulants is one of the options for the treatment of 
disseminated intravascular coagulation and venous thromboembolic disease [16]. Fucoidan is a 
promising natural anticoagulant. It has shown significant heparin-like anticoagulant activity [17–
20]. Effective inhibition of thrombin and factor Xa by fucoidan from F. evanescens has been 
described by Lapikova et al. [21]. The antithrombotic activity of fucoidan from Saccharina latissima 
has been confirmed by Ustyuzhanina et al. [22]. Recently, we have reported a significant 
heparin-like anticoagulant effect for an ointment with 15% of fucoidan after topical application on 
rats [23]. 
Little is known about the pharmacokinetics of fucoidan. Few papers have reported on the 
pharmacokinetics of this polysaccharide after peroral administration [24–26]. However, the 
pharmacokinetics of fucoidan after topical application is not described. Recently, we have 
developed the method of measuring the anti-activated factor X (anti-Xa) activity by an amidolytic 
assay and successfully applied it to the pharmacokinetics and tissue distribution of fucoidan [26]. In 
this study we report the pharmacokinetics of fucoidan after topical application of ointment to rats. 
2. Results and Discussion 
The topical application is considered the most convenient and comfortable way for drug 
delivery to patients. However, the skin is also an exceptionally effective barrier that prevents the 
permeation of most commercially available transdermal drugs [27–29]. The diffusional barrier is 
localized in the stratum corneum of skin, and prevents entry of molecules with molecular weight 
(Mw) over 350 Da [30]. Yang et al. have shown that fucoidan with Mw 10–300 kDa has exhibited the 
strongest anticoagulant activity [31]. Due to the relatively large Mw, negative charge and 
hydrophilicity fucoidans generally penetrate the skin poorly [10]. To overcome this disadvantage, 
we have developed an ointment formulation for fucoidan, which shows significant anticoagulant 
activity after topical application on rats [23]. This fucoidan, with an average Mw 750 kDa, contains 
79.5% neutral carbohydrates, 27.0% sulfate residues, and 0.7% uronic acid. Transcutol was used as 
the penetration enhancer, and polyethylene glycol as the surfactant [32]. The anticoagulant activity 
of our formulation that contains fucoidan is in agreement with previously published studies, where 
fucoidan-possessing high sulfate, and low uronic acid content, display high anticoagulant activity 
[17,33]. In line with our previous studies, we considered studying the pharmacokinetics of the 
ointment with fucoidan (OF). 
Following topical application, drugs that reach the dermis can be either systemically absorbed 
or continue to diffuse into underlying tissues. Drug permeability across the skin has often been 
regarded as the primary criterion for the efficiency of transdermal delivery without proper 
assessment of drug disposition in local tissues. In this study, the local tissue disposition and systemic 
absorption of fucoidan were investigated after topical, and intravenous (i/v) administration in rats, 
in order to evaluate the feasibility of transdermal delivery of fucoidan for local and systemic effects. 
Single doses (50–150 mg/kg) and multiple doses (100 mg/kg during five days) of a topical 
application of ointment with fucoidan caused no signs of dryness, erythema, hemorrhage, edema or 
erosion/excoriation at application sites in rats.  
Based on previously published data [25], the anti-Xa activity was selected as the biomarker for 
our study of pharmacokinetics of fucoidan. The previously developed and validated amidolytic 
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assay for fucoidan in rat plasma was revalidated for the skin tissue. The calibration curve for 
fucoidan was linear over a concentration range of 0.014–1.13 μg/g (Figure 1). The fucoidan 
concentration in the skin tissue was calculated according to the equation: у = −10.51x + 2.764; (R2 = 
0.9904), where х is the optical density (o.u.) and у is the concentration of fucoidan (μg/g skin tissue). 
The validation data for the method of determining fucoidan concentration in the skin tissue are 
presented in Table 1. 
 
Figure 1. The calibration curve for the calculation of fucoidan in the skin tissue. 
Table 1. The validation data for the method determining fucoidan in the skin tissue. 
Parameter Range 
Accuracy, % 
ULOQ (1.13 μg/g) 0.6–3.4 
Middle-quality control (0.56 μg/g) 1.7–9.7 
Low-quality control (0.14 μg/g) 9.2–14.8 
LLOQ (0.014 μg/g) 2.9–12.3 
Intraday/Interday precision (RSD), % 
ULOQ (1.13 μg/g) 0.9–1.9/3.5 
Middle-quality control (0.56 μg/g) 3.4–6.1/7.6 
Low-quality control (0.14 μg/g) 2.3–5.0/6.8 
LLOQ (0.014 μg/g) 3.7–4.7/10.9 
LOD, μg/g 0.0035 
ULOQ, upper limit of quantification; LLOQ, lower limit of quantification; LOD, limit of detection. 
After revalidation, the method was successfully applied for the analysis of fucoidan in plasma 
and tissues. The concentration-time profiles of fucoidan in plasma after i/v administration and 
topical application to rats are shown in Figure 2. 
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Figure 2. Fucoidan concentrations in plasma after i/v administration (100 mg/kg) and topical 
application (100 mg/kg) in rats (mean ± SD, n = 5). 
The plasma profile in rats after i/v administration (100 mg/kg) exhibited two exponential phases 
with a relatively long elimination half-life of 9.47 ± 2.34 h (Table 1). The topical application of the 
ointment with the same dose of fucoidan (100 mg/kg) resulted in long sustained profiles in plasma 
(Figure 2). Based on the concentration-time profiles data, the plasma half-life and the bioavailability 
of fucoidan after topical application were estimated to be 20.75 ± 9.43 h and 17.7 ± 7.7% of the applied 
dose, respectively. The longer half-life and low bioavailability of fucoidan after topical application 
was probably due to the quick drug penetration and restrain in the skin as shown in Table 2. The 
significant reservoir function of the skin was first discussed by Vickers [34]. However, the reservoir 
capacities of the skin were found to vary widely for different drugs, and substances with lower 
diffusivities in the stratum corneum exhibited a more prominent skin depot formation [35]. The 
reservoir function of the skin is an important determinant of the duration of action of a transdermal 
drug [36]. 
Table 2. Pharmacokinetic parameters of fucoidan after single and repeated dose administration to 
rats. 
Sample 
Dose Parameter  
(mg/kg) AUC0–48 (μg·h/mL)  MRT (h) T1/2 (h) Cmax (μg/mL) Tmax (h) 
Single dose 
Plasma, i/v 100 10.83 ± 0.32 8.08 ± 1.92 9.47 ± 2.34 9.15 ± 0.60 - 
Plasma, topical 50 0.74 ± 0.11 20.99 ± 10.74 14.41 ± 7.52 0.12 ± 0.02  1.20 ± 0.44 
Plasma, topical 100 1.92 ± 0.94 30.20 ± 13.70 20.75 ± 9.43 0.15 ± 0.01 1.00 ± 0.00 
Plasma, topical 150 3.08 ± 0.21 29.94 ± 4.51 20.60 ± 3.07 0.18 ± 0.01 1.20 ± 0.01 
Skin*, topical 100 0.94 ± 0.11 9.00 ± 4.36 6.28 ± 3.46 0.27 ± 0.01 0.25 ± 0.00 
Striated muscle*, dermal 100 2.22 ± 1.18 16.15 ± 4.40 10.64 ± 9.94 0.31 ± 0.12 1.80 ± 1.30 
Repeated doses (5 days) 
Plasma, topical 100 2.10 ± 0.69 41.12 ± 10.70 28.06 ± 7.92 0.18 ± 0.05  1.10 ± 0.55 
* AUC0–48 (μg·h/g) for tissues; Cmax (μg/g) for tissues. AUC0–48, the area under the curve; MRT, mean residence 
time; T1/2, apparent half-life of elimination. The results are expressed as the mean ± SD (n = 5). 
Table 3 shows the fucoidan concentrations in the skin and muscle tissues of the rats after topical 
application at the dose of 100 mg/kg. The data indicates that a significant amount of the penetrated 
drug is retained in the skin after the topical dose. The fucoidan concentrations in the skin during the 
first hour after sampling remain nearly the same, suggesting that the epidermis is saturated with the 
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drug. However, appreciable amounts of fucoidan (0.27 ± 0.16 and 0.24 ± 0.07 μg/g tissue) were found 
in the 1 and 2 h muscle samples. The initially high muscle-plasma (M-P) concentration ratio of 1.18 is 
indicative of direct permeation of fucoidan into the muscle tissues after the topical application. 
Moreover, at 1 and 2 h postdose, drug concentrations in the muscle have increased, despite 
increased plasma concentration, resulting in the increased M-P ratios of 1.77 and 1.75, respectively. 
The increased fucoidan concentrations in the muscle samples could be attributed to the slow 
removal of the drug by the systemic circulation. 
Table 3. Fucoidan concentrations (μg fucoidan/ g tissues or mL plasma) following topical 
application (100 mg fucoidan /kg weigh rat) of ointment (Mean ± SD). 
Tissues 15 min 30 min 1 h 2 h 4 h 6 h 8 h 
Skin 0.274 ± 0.013 0.231 ± 0.028 0.224 ± 0.029 0.138 ± 0.032 0.105 ± 0.010 0.092 ± 0.008 0.050 ± 0.046 
Muscle 0.141 ± 0.033 0.162 ± 0.049 0.268 ± 0.156 0.238 ± 0.067 0.196 ± 0.053 0.150 ± 0.037 0.115 ± 0.043 
Plasma 0.119 ± 0.017 0.124 ± 0.014 0.151 ± 0.013 0.136 ± 0.013 0.127 ± 0.012 0.121 ± 0.019 0.102 ± 0.014 
M-P ratio 1.18 1.31 1.77 1.75 1.54 1.24 1.13 
It was previously shown that oral administration of fucoidan to rats leads to a rapid increase of 
concentration in the stationary state one hour after administration and lasts for the next six hours. 
Based on the data, the elimination half-life from blood plasma, calculated on oral administration, 
could be estimated as 3.44 ± 1.70 h [26]. Figure 2 shows that the application of the OF resulted in 
long, sustained concentration-time profiles in plasma, reaching the steady state concentration at 1 h 
postdose and lasting for the next ~30 h. Based on the concentration-time data, the plasma half-life 
and the bioavailability of fucoidan after topical application (100 mg/kg) were estimated to be 20.75 ± 
9.43 h and 17.7% of the applied dose, respectively. The longer half-life of the fucoidan after topical 
application was probably, in part, due to the large drug accumulation in the skin, as shown in the 
skin disposition study using rats. 
It was found that the pharmacokinetics of fucoidan after topical OF application was linear in 
the range of 50–150 mg/kg. AUC0-48, T1/2 and Сmax evidently increased after the dose increased, but 
wide data variations were observed (Table 2). Since in the experiment with a single administration of 
fucoidan, the linear pharmacokinetics was established, one dose level (100 mg/kg) was used in 
experiments with repeated dose administration. 
Figure 3 demonstrates the concentration-time profiles of fucoidan after topical application of 
OF in plasma after a single dose (100 mg/kg) and after repeated daily dosing with 100 mg/kg of 
fucoidan during five days. After the repeated dose of topical application, fucoidan exhibited higher 
apparent half-life of elimination (28.06 ± 7.92 h) and long circulation time (41.12 ± 10.70 h). However, 
the difference was not statistically significant when compared to the single dose administration, 
which evidenced about the absence of its accumulation in the plasma after the repeated application 
(Table 2).  
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Figure 3. The mean plasma profiles of fucoidan after topical application of OF to the rats after single 
(100 mg/kg) and repeated doses (100 mg/kg during 5 consecutive days) 
The topical application of formulations containing fucoidan has been reported as an effective 
method for the treatment of atopic dermatitis, dermal burns, oral herpes, and as an anticoagulant 
[11,12,15,23]. It is known that the rodent skin does not always have identical permeation properties 
as the human skin. In human, permeability of hydrophilic drugs is remarkably lower than that in 
animals [37]. It is necessary to note that systemic exposure in humans may be significantly 
overestimated if the risk assessment is based only on the results of an in vivo study [38]. Future 
studies in humans are therefore required. Since this is the first report about the pharmacokinetics of 
fucoidan after topical application, the present study may shed new light on the penetration of 
fucoidan through the skin and the rationality of transdermal formulations with this polysaccharide.  
3. Materials and Methods   
3.1. Chemicals 
Fucoidan with the average molecular mass 735 kDa was obtained from MMBI KSC RAS, 
Murmansk, Russia. Fucoidan was extracted from F. vesiculosus as described previously [25]. 
Poloxamer 407 (Kolliphor® P 407), Polyoxyl 40 hydrogenated castor oil (Kolliphor® RH40), 
polyethylene glycol 400 (Kollisolv® PEG 400) were provided by BASF (Ludwigshafen, Germany). 
Extra-virgin olive oil was purchased at a local market. Diethylene glycol monoethyl ether 
(Transcutol® P) was a gift from Gattefossé (Saint-Priest, France). Acepromazine (Fermenta Animal 
Health Co., Kansas City, MO, USA), ketamine (Fort Dodge Laboratories, Inc., Fort Dodge, IA, USA), 
xylazine (Miles Inc., Shawnee Mission, KS, USA), and other chemicals were used as received from 
the suppliers. 
3.2. Animals 
Male outbred rats (n = 250) were obtained from Rapplovo animal house (St. Petersburg, Russia). 
The animals were kept under standard conditions with a 12-h light–dark cycle, at an ambient 
temperature (22 ± 2 °C), and relative humidity of 60 ± 10%. They had free access to food (Standard 
diet: Volosovo, Russia) and water ad libitum. Rats (n = 5 per time point) fasted overnight before the 
experiment. Rats were divided into five groups: group A, intravenous (i/v) injection of fucoidan 
(single dose, 100 mg/kg) for determination absolute bioavailability; groups B, C and D, topical 
application of 15% fucoidan ointment (single dose of 50, 100 and 150 mg/kg, respectively); and 
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group E, topical application of 15% fucoidan ointment (100 mg/kg, once a day) during 5 days. The 
rationality of this dose selection is supported by a previous report [26]. Four groups were treated 
with the 15% fucoidan ointment on the dorsal site (3 cm × 3 cm) for sampling at different time points 
(15, 30 min, 1, 2, 4, 6, 8, 24, and 48 h postdose). One day prior to dosing, the ventral and dorsal areas 
of the skin were carefully shaved with an electric clipper (Oster, Model A-2, Milwaukee, WI, USA) 
under light anesthesia using intraperitoneal injection of a mixture containing ketamine and xylazine 
(10:1 v/v, 50 mg/mL). No signs of skin damage were observed after shaving. Regarding application, 
350, 700 and 1000 milligrams of the 15% fucoidan ointment was applied uniformly on the marked 
area of the dorsal skin, approximately 3 cm × 3 cm, and allowed to dry. After application, the rats 
were euthanized in a CO2 chamber at different time points (15, 30 min, 1, 2, 4, 6, 8, 24, and 48 h), and 
the blood was collected by cardiac puncture. The blood was transferred to sodium citrate tubes, 
centrifuged at 3000× g for 15 min at 4 °C, and then the plasma was collected and stored at −20 °C.  
The skin and muscle were cut into small pieces to determine the amount of fucoidan in the 
viable skin (epidermis and dermis) and muscles. Prior to excising tissue samples, the dosed area of 
the skin was completely washed with wetted cotton in 50% ethanol. Each tissue sample was 
precisely weighed and homogenized (Polytron PT-MR 1600E, Kinematica AG, Lucerne, 
Switzerland) in 0.15 μM Tris-HCl buffer (pH 8.4). After vortex mixing and centrifugation for 15 min 
at 3000× g (EBA21 tabletop centrifuge, Hettich, Westphalia, Germany), the upper phase was 
collected and used for an amidolytic assay. 
An aqueous solution of fucoidan (10 mg/mL) at the doses of 100 mg/kg was used for the i/v 
administration to rats. After administration, the rats were euthanized in a CO2 chamber at the time 
points of 5, 15, 30 min, 1, 2, 4, 6, 8, 24, and 48 h. The animals from group E were euthanized on the 5th 
day of experiments. The blood was collected in sodium citrate tubes by cardiac puncture, 
centrifuged at 3000× g for 15 min at 4 °C, plasma was collected and stored at −20 °C. 
Experiments were performed according to the directive 267, “Regarding the statement of 
regulation of laboratory practice of the Ministry of Health of the Russia” (2003) and the EEC 
Directive of 1986 (86/609/EEC), and were approved by the Ethical Commission of the St. Petersburg 
Institute of Pharmacy (Leningrad Region, Vsevolozhsky District, Kuzmolovo P 245, Russia). 
The ointment was prepared as described previously [23]. Shortly after, an appropriate amount 
of poloxamer was slowly added to water, and the mixture was left in a refrigerator until becoming a 
clear solution. Fucoidan and Transcutol were dissolved in a water solution of poloxamers and then 
mixed into the cold solution. The solution was incubated at room temperature until a homogeneous 
gel was formed. Separately, olive oil, kolliphor and PEG 400 were mixed at room temperature. Then 
a fucoidan phase was added to the oil phase with vigorous stirring. 
3.3. Analysis of Fucoidan in Plasma and Tissue 
The amount of fucoidan in plasma and tissues was determined by the amidolytic assay using 
ReaChrom Heparin kit (Renam, Russia) as described previously [26]. Optical density was recorded 
at 405 nm on a microplate spectrophotometer X-Mark (Bio-Rad, Hercules, CA, USA). The endogenous 
level of products reacted with the heparin kit was subtracted at each time point in each sample. The 
method was validated according to the International Conference on Harmonization (ICH) guidelines 
[39,40].  
3.4. Pharmacokinetic and Statistical Analysis 
A PKSolver add-in for the Excel was used for the pharmacokinetic calculations of fucoidan in 
tissues and plasma. The parameters were calculated from the concentration-time data using a 
noncompartmental pharmacokinetic model as described previously [26]. The results are expressed 
as the mean ± standard deviation (SD) (n = 5 for each time point).  
The bioavailability of fucoidan from the ointment was calculated by comparing the area under 
the concentration-time curve for topical dose (AUCt, 0–48 h) and that for i/v dose (AUCiv, 0–48 h). 
The Student t-test was used for the test of statistical difference and p values of less than 0.05 were 
considered significant. 
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4. Conclusions 
Although there is limited available literature, research on the fucoidan use for transdermal 
therapy and its pharmacokinetics has been increasing. Our results indicate that fucoidan in 
ointments penetrate the skin barrier and accumulate in the striated muscle. Our results support the 
rationality of the topical application of fucoidan formulations.  
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